Drug intelligence / Profile preview

peginterferon alfa-2b + tenofovir alafenamide

Development stage: Preclinical
Lead developer: Gilead Sciences
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Subcutaneous, Oral

Overview

A combination therapy that pairs peginterferon alfa-2b, a pegylated form of recombinant interferon with immunomodulatory properties, and tenofovir alafenamide, a nucleotide analogue prodrug that inhibits HBV DNA polymerase. This regimen combines the antiviral potency of tenofovir alafenamide with the immune-enhancing effects of peginterferon to potentially achieve higher rates of HBsAg clearance and functional cure in chronic hepatitis B patients than either agent alone.

Brand names: PegintronSylatron
Other names: PEG-IntronPeg Intron RP

Targets

HBV Pol (Hepatitis B virus polymerase)IFNAR (Immune system modulation via type I interferon receptor)

Beyond the preview

Go deeper on peginterferon alfa-2b + tenofovir alafenamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on peginterferon alfa-2b + tenofovir alafenamide.

Explore the full profile